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We report a case of pathologically confirmed tumefactive multiple sclerosis (MS) followed
shortly thereafter by the diagnosis of an oligoastrocytoma. The complexity of diagnosis
and management of concomitant presence of tumefactive MS and glial cell tumors is
discussed.
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Case Report
A69-year-oldman presented to ourNeurosurgery Service with a 2-month history of trouble writing,
poor coordination of his right hand, and word finding difficulties. Initial neurological examination
was unremarkable. Medical history was remarkable for hypertension, dyslipidemia, coarctation of
aorta (diagnosed at age 18 and corrected with surgery), and L4–L5 laminectomies due to significant
pain. There was a strong family of cancer including a brother (deceased age 77) with glioblastoma
(GBM) and a daughter (deceased age 34) with osteosarcoma (unknown location).
Routine blood chemistries and CBC were unremarkable. MRI of the brain, with and without
contrast, showed a left frontal, ring-enhancing mass measuring 2 cm 2.3 cm with substantial
edema (Figure 1). He was started on intravenous (IV) methylprednisolone 1 g daily for 5 days.
He then had a craniotomy with partial resection of the mass lesion. Pathologic evaluation of the
resected tissue demonstrated reactive gliosis with CD-68 macrophages most likely consistent with a
demyelinating lesion (Figure 2). After surgery, the Neurology Service was consulted.
Hewas weaned off steroids. He experienced considerable improvement of his dexterity and ability
to concentrate.
About 10months later, an MRI of the brain was taken at follow-up, showing no evidence of local
recurrence of the left frontal lesion. There were patchy hyperintensities in the right occipital and left
frontal areas. At that time, he was asymptomatic, and his clinical examination was unremarkable.
Three months later, he presented with difficulty concentrating and poor short-term memory.
MRI of the brain now showed increased size of the right occipital and parietal lobe lesions, with a
new area of occipitoparietal ring enhancement (Figure 3A).
A 5-day course of high-dose IVmethylprednisolone was started for a possible recurrent demyeli-
nating process. Cerebrospinal fluid (CSF) analysis showed normal protein levels with nowhite blood
cells (WBC), glucose 63mg/dl (60%), and 0.77 IgG index (with serum IgG 622mg/dl). Myelin basic
protein (MBP) and serum neuromyelitis optica (NMO) antibodies were negative. CSF sampling for
oligoclonal bands (OGB) was positive. Somatosensory evoked potentials (SSEPs) were normal and
visual evoked potentials (VEPs) were uninterpretable.
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FIGURE 1 | Left image: axial T2 FLAIR showing 2cm 2.3 cm left frontal mass with substantial edema. Middle image: sagittal T1 post-contrast image
showing contrast enhancement in a “ring-like” pattern. Right image: axial T2 FLAIR showing residual changes consistent with partial resection of the previous
ring-enhancing left frontal mass.
FIGURE 2 | Pathological specimen of the left frontal lobe lesion. Left
image: H&E section showing white matter with reactive gliosis (reactive
astrocytes with abundant eosinophilic cytoplasm). Right image: Luxol fast
blue showing absence of myelin.
He was discharged on a tapering dose of oral steroids. He was
subjectively better, but became symptomatic again with gener-
alized weakness, more prominent on the left side. The weak-
ness slowly progressed until an initial dose of natalizumab was
given. The patient then experienced abrupt worsening of symp-
toms. Neurological examination showed left-sided hemiparesis,
left hemibody neglect, and left inferior homonymous quadran-
tanopia. MRI of the brain revealed an increased area of enhance-
ment in the deep, right parietal lobe with mass effect (Figure 3B).
The patient was taken to theOR for resection of the lesion. Pathol-
ogy showed oligoastrocytoma; grade III on cytology. Chemother-
apy with temozolamide (standard protocol) and radiation therapy
(5940 cGy) in 33 fractions to the right parietal lobe lesion were
initiated. The patient then developed worsening left leg weakness
and further MRI of the spine showed nodular enhancing lesions
of the lumbar spine consistent with leptomeningeal metastasis. At
that point, bevacizumab was initiated in addition to adjustment
in the dexamethasone dose. The patient unfortunately was lost to
follow-up thereafter.
Discussion
Occurrence of multiple sclerosis (MS) and brain tumors has been
reported <50 times in the literature, since first described by Bosch
in 1912 (1). Concurrence of MS and cerebral glial cell tumors is
uncommon, but has been described (2, 3). Whereas some authors
believe that tumors develop from neoplastic transformation of
reactive glial cells in the involved area of demyelination, others
FIGURE 3 | (A) Sagittal T1 post-contrast showing large area of right
occipitoparietal lesion with a ring-like enhancing pattern (left image) and axial
T2 FLAIR MRI showing substantial peri-lesional edema (right image).
(B) Sagittal T1 post-contrast MRI showing marked increase in the size of the
right parietal lobe lesion with surrounding local edema and enhancement.
believe that this is purely coincidental (2–7). Tumors and plaques
are not contiguous in all reported cases and multicentricity, sim-
ilar to MS plaques, is reported in about 30% of these tumors (8,
9). In most cases, MS is the initial pathology with subsequent
development of cerebral glioma, most frequently of the astrocytic
subtype type (6).
Tumefactive demyelinating lesions (TDLs) are defined as large
(>2 cm) demyelinating lesions occurring either as solitary lesions
or as a few separated lesions with little vasogenic edema, and
incomplete or open ring-enhancing lesions (10, 11). Like brain
neoplasms, TDLs enhance and exhibit mass effect, often making
it difficult to differentiate TDL from neoplasm.
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MRI is the most sensitive technique for depicting demyeli-
nating disease. A study by Kim and colleagues (12) showed
that comparing the corresponding areas of CT hypo-attenuation
with the respective MR enhancing regions is specific for distin-
guishing TDL from primary glioma, or CNS lymphoma. Com-
bined modalities of MR and non-contrast CT are significantly
more accurate than MRI imaging alone for differentiating these
entities (12). Magnetic resonance spectroscopy (MRS) can dif-
ferentiate between astrocytic tumors and demyelinating lesions
by showing (not only in MS but also in low-grade gliomas)
increased myoinositol peaks (indicative of reactive gliosis) and
decreases in N-acetylaspartate peaks (indicative of neuronal cell
loss). Tumors also show decreases in N-acetylaspartate but have
typical increased choline peaks (indicating rapid mitotic activity)
and increased lactate peaks (indicative of intratumoral glycolysis)
(13). When lesions manifest with tumefaction mimicking brain
gliomas, or CNS lymphoma, the diagnosis will still be made by
histopathological studies showing foamy macrophages, reactive
gliosis with lack of myelin in MS and variable degrees of high-cell
density, mitosis, nuclear atypia, microvascular proliferation, and
necrosis with gliomas (14).
Management of high-grade gliomas often requires cytore-
ductive therapy followed by adjuvant therapy with radiother-
apy (XRT) and/or chemotherapy (15). Additional morbidity may
occur when giving XRT to a patient with glioma who has a
concomitant demyelinating disorder (16). Patients with MS and
glioma have survival-times identical to those observed in patients
not suffering from MS. Moreover, the coexistence of MS and
brain tumor does not influence the clinical evolution of either of
these pathologies, and despite extensive area of demyelination, the
course of TDLs is rather benign with unpredictable progression to
MS as compared to the course of brain gliomas (11, 17).
Author Note
This case submission met all of the requirements for publication
under the rules of the LoyolaUniversity Stritch School ofMedicine
Institutional Review Board.
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